Citigroup
CKPT

Citigroup’s Checkpoint Therapeutics CKPT Stock Holding History

Citigroup’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,662
Closed -$88.5K – 5637
2024
Q4 		$88.5K Buy
+27,662
New +$93.8K ﹤0.01% 4900
2022
Q2 		– Sell
-370
Closed -$7K – 6280
2022
Q1 		$7K Buy
+370
New +$7.95K ﹤0.01% 5676
2021
Q2 		– Sell
-343
Closed -$11K – 6156
2021
Q1 		$11K Sell
343
-590
-63% -$19.8K ﹤0.01% 5573
2020
Q4 		$25K Buy
933
+716
+330% +$18.1K ﹤0.01% 6501
2020
Q3 		$6K Sell
217
-325
-60% -$7.8K ﹤0.01% 6887
2020
Q2 		$11K Sell
542
-10
-2% -$182 ﹤0.01% 6992
2020
Q1 		$8K Buy
552
+61
+12% +$1.08K ﹤0.01% 7115
2019
Q4 		$8K Buy
491
+370
+306% +$6.2K ﹤0.01% 7259
2019
Q3 		$3K Sell
121
-525
-81% -$14.4K ﹤0.01% 7444
2019
Q2 		$20K Buy
+646
New +$25.4K ﹤0.01% 7081

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Citigroup's CKPT Position: Q1 2025 in Review

Citigroup sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 27,662 shares — an estimated $88.5K sold.

Citigroup first reported a position in CKPT in Q2 2019 and held it in 10 quarters. The position peaked at $88.5K in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Citigroup reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citigroup sold 27,662 Checkpoint Therapeutics shares in Q1 2025, an estimated $88.5K.
  • Citigroup first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 10 quarters.
  • Citigroup's Checkpoint Therapeutics position peaked at $88.5K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.